- Top Workplaces
- TriSalus Life Sciences
TriSalus Life Sciences
TriSalus Life Sciences® was created to develop and commercialize an innovative approach for the treatment of liver and pancreatic tumors. Our platform approach addresses immune dysfunction in liver and pancreatic tumors by combining immunotherapy drugs with highly effective drug delivery technology.
Purpose
TriSalus Life Sciences is an immunotherapy company on a mission to extend and improve the lives of patients living with liver and pancreatic tumors.
Vision
To overcome key barriers to treatment success in liver and pancreatic tumors, allowing patients to realize the promise of immunotherapeutic treatments.
By integrating an immunotherapeutic with innovative drug delivery technologies, TriSalus' platform seeks to address two of the most significant barriers that limit the effectiveness of current treatments for liver and pancreatic tumors: immunosuppression and high intratumoral pressure.
By integrating an immunotherapeutic with innovative drug delivery technologies, TriSalus' platform seeks to address two of the most significant barriers that limit the effectiveness of current treatments for liver and pancreatic tumors: immunosuppression and high intratumoral pressure.
Mission
To extend and improve the lives of patients living with liver and pancreatic tumors through our immunotherapy platform that seeks to address current challenges to treatment.
TriSalus is studying the ability of SD-101, a potentially first-in-class, investigative TLR9 agonist, to reactivate the immune system within the liver and pancreas to enable more durable responses to other immunotherapeutics (e.g., checkpoint inhibitors) and improve patient outcomes. The platform, which leverages TriSalus’ proprietary Pressure-Enabled Drug Delivery™ (PEDD™) method of administration, modulates pressure and flow within blood vessels to improve the amount of therapy delivered to the tumor. While meaningful progress in these difficult-to-treat diseases will not be easy, TriSalus is focused on advancing science and technological innovation to transform outcomes for patients.
TriSalus is studying the ability of SD-101, a potentially first-in-class, investigative TLR9 agonist, to reactivate the immune system within the liver and pancreas to enable more durable responses to other immunotherapeutics (e.g., checkpoint inhibitors) and improve patient outcomes. The platform, which leverages TriSalus’ proprietary Pressure-Enabled Drug Delivery™ (PEDD™) method of administration, modulates pressure and flow within blood vessels to improve the amount of therapy delivered to the tumor. While meaningful progress in these difficult-to-treat diseases will not be easy, TriSalus is focused on advancing science and technological innovation to transform outcomes for patients.
Additional Culture Details
We’re industry innovators, engineers, medical doctors, and scientists. Many of us bring years of experience from biotechnology companies and top academic research institutions. We’ve come to TriSalus for the opportunity to transform a challenging area of oncology. Whether we’re studying therapies, engineering new device technologies, or driving key business efforts, we’re all passionate about making a difference for patients.
Liver and pancreatic tumors are stubbornly difficult to treat. We aim to change that by enabling patients with these cancers to realize the promise of immunotherapy through our innovative platform approach. In the lab, the clinic, the office, and the field, we’re working together to achieve this goal. Our desire to provide new hope for patients drives our relentless curiosity, innovation, and scientific rigor.
TriSalus is headquartered in Westminster, Colorado, with additional locations in Illinois and Rhode Island.
Liver and pancreatic tumors are stubbornly difficult to treat. We aim to change that by enabling patients with these cancers to realize the promise of immunotherapy through our innovative platform approach. In the lab, the clinic, the office, and the field, we’re working together to achieve this goal. Our desire to provide new hope for patients drives our relentless curiosity, innovation, and scientific rigor.
TriSalus is headquartered in Westminster, Colorado, with additional locations in Illinois and Rhode Island.
Values
- Passion
- Transforming the lives of patients suffering from solid tumors, we are united by a common path to purpose.
Recent Awards
Company Snapshots
